Xilio Therapeutics Reports Q3 Earnings Beat on Revenue and EPS
Xilio Therapeutics (XLO) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.30, representing a beat of $0.64 compared to consensus estimates. Despite the beat, quarterly revenue reached $9.98 million, which marks a 47.7% decrease year-over-year. However, this figure still surpassed market projections by $5.06 million, signaling stronger-than-anticipated top-line performance for the period.
Tickers: $XLO
Topics: earnings beat GAAP EPS revenue decline